IDH1 and glioblastoma: Based on the recognition of IDH mutations as key disease-defining features of astrocytomas and oligodendrogliomas that reliably distinguish them from glioblastomas, assessment of the IDH status has become an integral part of the diagnostic algorithm for glioma classification.